Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...
Tag - Kumaraguru Raja
Reporting on the healthcare industry’s corporate and clinical developments, executive moves and views from the Street.
Copyright © 2020 BioTuesday Publishing Corporation - Privacy Policy